TSEE

23.8871.78%

Kodiak Sciences tumbles 8%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Kodiak Sciences (KOD.US) tumbled nearly 8% during regular trading to $102.40.

The stock is up 176.61% over the past six months and up 266.24% year to date. Volume was 4.32 times its average.

The Nasdaq Composite is down 2.41% over the past five sessions and up 6.03% year to date.

The company reported a third-quarter net loss of $66.2 million, with GAAP and basic loss per share at $1.05, exceeding the LSEG consensus by $0.01. The wider year-over-year loss was primarily driven by increased research and development expenses for clinical trials.

Kodiak held $88.7 million in cash as of quarter-end and raised an additional $69.0 million through equity financing after the period, funds expected to support operations into 2027. On the pipeline front, the company plans to submit a Biologics License Application for Zenkuda by year-end and will announce initial Phase III results for KSI-101 in December 2026.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.